openPR Logo
Press release

Pharmacy OneSource Announces Free Webinar on Management of New Anticoagulants

01-28-2011 01:13 PM CET | Health & Medicine

Press release from: Pharmacy OneSource

Understanding the differences in new oral anticoagulants for proper administration
 
Bellevue, WA – Pharmacy OneSource, software-as-a-service provider of Sentri7, a real-time clinical surveillance system, is pleased to announce a complimentary webinar presented by Michael Gulseth, Pharm.D., BCPS, in "The New Oral Anticoagulants: Cause for Celebration or Concern?"

New, oral anticoagulants present one of the biggest paradigm shifts that has ever happened in the world of anticoagulation management. To assure the safe and effective use of these medications, it is critical that practitioners understand their pharmacokinetic and pharmacodynamic differences. Further, this knowledge must be combined with a critical evaluation of clinical trials on which their approval is or will be based. Finally, hospitals, integrated health systems, and clinics will need to take significant and numerous actions to assure these agents are used safely in a systematic fashion. The goal of this webinar is to provide the knowledge base required to begin taking these actions.

The New Oral Anticoagulants: Cause for Celebration or Concern?
DATE: Wednesday, February 9, 2011
TIME: 1:00 PM - 2:00 PM EST
WHERE: http://www.pharmacyonesource.com/webinars

About the Presenter:
Michael P. Gulseth, Pharm.D., BCPS is the Program Director for Anticoagulation Services as Sanford USD Medical Center in Sioux Falls, SD. Dr. Gulseth received his Doctor of Pharmacy degree in 1999 from North Dakota State University in Fargo, North Dakota He completed residency training at United Hospital in St. Paul, Minnesota. Dr. Gulseth is lead author and editor of Managing Anticoagulation Patients in the Hospital: the Inpatient Anticoagulation Service, published in 2007 by the American Society of Health-System Pharmacists.

Dr. Gulseth was a member of the Editorial Advisory Board of the American Journal of Health-System Pharmacy. Dr. Gulseth is an active member of several professional pharmacy organizations, including the American Society of Health-System Pharmacists, the Minnesota Society of Health-System Pharmacists (with whom he served as president), the South Dakota Society of Health-System Pharmacists, and the American College of Clinical Pharmacy. His research interests include evaluation of antithrombotic therapies in the inpatient setting and evaluation of the benefits of pharmacist-managed inpatient anticoagulation services.

About Pharmacy OneSource (www.pharmacyonesource.com)
Pharmacy OneSource is healthcare’s #1 Software-as-a-Service (SaaS) provider. Our more than 100 innovative team members provide best-in-class, SaaS solutions to current and future challenges within health-systems worldwide. Our SaaS solutions contribute to swift and safe healthcare through earlier, easier and better access to data. More than 1,300 healthcare organizations worldwide utilize our HIPAA compliant web-based services: Accupedia, Amplifi, MedBoard, Quantifi, ScheduleRx, Sentri7, Simplifi 797, and VeriForm.

Pharmacy OneSource
3535 Factoria Blvd. SE #440
Bellevue, WA 98006

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pharmacy OneSource Announces Free Webinar on Management of New Anticoagulants here

News-ID: 160260 • Views:

More Releases from Pharmacy OneSource

Richie's Specialty Pharmacy Selects Simplifi 797 for USP 797 Compliance
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Richie's Specialty Pharmacy, LLC has selected its Simplifi 797 software for achieving sterile compounding compliance. Simplifi 797 is a web-based application that automates, integrates and streamlines quality activities and documentation related to U.S. Pharmacopeia's Chapter 797 guidelines. The software manages task scheduling for environmental monitoring and automates the reporting of exceptions and compliance. "Simplifi
Pharmacy OneSource® Partners with CriticalPoint™ to Offer the Next Generation …
Bellevue, Washington – Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Pharmacy OneSource® has released a new version of Simplifi 797®, a web-based quality assurance software for USP chapter 797 compounding compliance. The upgraded version of Simplifi 797 includes CriticalPoint's education program, which gives users unlimited access to 42 hours of ACPE-approved continuing education credits supporting compliance with USP Chapter . Lessons
Wolters Kluwer Health Unveils Integration between UpToDate and Sentri7
Bellevue, WA -- Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that UpToDate's clinical knowledge system has been integrated with Sentri7 surveillance software by Pharmacy OneSource. This partnership of evidence-based clinical information through UpToDate and clinical patient surveillance from Sentri7 offers healthcare providers actionable information at the point of care to make better decisions in directing patient care. UpToDate synthesizes the most recent medical

More Releases for Pharm

Fenbendazole Market Size, Share and Forecast By Key Players-Jin Dun Pharm, Shand …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Fenbendazole market is anticipated to grow at a compound annual growth rate (CAGR) of 16.05% between 2024 and 2031. The market is expected to grow to USD 68 Billion by 2024. The valuation is expected to reach USD 192.77 Billion by 2031. The fenbendazole market is experiencing notable growth due to increasing awareness of parasitic infections in both
Revolutionizing Revenue: Dexlansoprazole Sustained Release Capsule Market Trends …
Worldwide Market Reports announces the publication of its most recently generated research report titled, "Dexlansoprazole Sustained Release Capsule Market - Forecast to 2030", which offers a holistic view of the Dexlansoprazole Sustained Release Capsule market through systematic segmentation that covers every aspect of the target market. Dexlansoprazole Sustained Release Capsule with 100+ market data Tables, Pie Chat, Graphs, and Figures spread through Pages and easy-to-understand detailed analysis. The information is
Paromomycin Sulfate Market 2030 by Top 10+ Players Pfizer,, Changrui Pharm,, ERF …
Paromomycin Sulfate is an antibiotic used to treat infections caused by certain parasites. It is commonly used to treat visceral leishmaniasis, a serious parasitic disease that affects the internal organs. The market for Paromomycin Sulfate is relatively small compared to other antibiotics, as it is primarily used to treat a specific type of parasitic infection. However, the market for Paromomycin Sulfate is expected to grow as the incidence of visceral
Fosfomycin Market to Witness Huge Growth by 2026 | Northeast Pharm, Ercros, Shin …
The Latest Released Fosfomycin market study has evaluated the future growth potential of Global Fosfomycin market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities
Clopidol Market updates, demand analysis, and expected growth forecast 2021-2027 …
Global “Clopidol” Market Size, Status, and Forecast 2021-2027. In-depth research accumulated to offer Latest insights about acute features of the global Clopidol market. This report provides a detailed overview of key factors in the Clopidol Market and factors such as driver, restraint, past and current trends, regulatory scenarios and technology development. The effect of the COVID-19 outbreak at the enterprise turned into completely assessed. Fully chance evaluation and enterprise recommendations
Paromomycin Market updates, demand analysis, and expected growth forecast 2021-2 …
The new study on the Global “Paromomycin Market” 2021-2027 analyzes the crucial capabilities, key infrastructures, major organizations, evaluates measures to attain potential success in the Paromomycin industry. Because of the in-depth overview of the Global Paromomycin market, the recent papers allow investors, traders, and manufacturers to plan some innovative techniques, and meanwhile, align them with operational and commercial enterprise models. Additionally, the Paromomycin market report offers crucial facets at the